Jeong M. Kim, Ph.D. - Calico
Skip to content
0%
Calico
Research & Technology
Research & Technology
Publications
Drug Development
Drug Development
Patients
Partnering
Leadership
Careers
Job Openings
PostDoc Program
Mission and Values
Leadership
Research & Technology
Drug Development
Patients
Partnering
Collaborator Profiles
People
Publications
News & Media
Press Releases
Calico Stories
Life at Calico
Careers
Job Openings
PostDoc Program
Contact Us
Back to Senior R&D Staff
Jeong M. Kim, Ph.D.
Head, Translational Medicine
Jeong taps his deep expertise in translational research, biomarker development, and precision medicine to advance Calico’s clinical development strategies.
About
Jeong leads the Translational Medicine Group, where he is responsible for developing early translational strategies, including predictive and pharmacodynamic biomarker plans, indication prioritization, and disease-relevant models. He also oversees the execution of IND-enabling pharmacology studies that support the progress of Calico’s translational programs.
Prior to joining Calico, Jeong served as Senior Director and Head of the Translational Research Department at Bristol Myers Squibb’s Tumor Microenvironment Thematic Research Center. He led scientific strategy, biomarker, and translational research efforts for solid tumors, driving innovative approaches to patient segmentation and biomarker discovery. Jeong’s career spans prominent roles at Bristol Myers Squibb, NGM Biopharmaceuticals, and Genentech, where he led diverse teams in advancing small molecule and antibody therapeutics in multiple disease areas. He has authored numerous publications and has contributed to several patents related to cancer immunotherapy and biomarker development.
Education:
Postdoc, Laboratory of Sasha Rudensky, University of Washington
Ph.D in Immunology, Washington University
B.Sc. in Microbiology and Molecular Genetic, University of California at Los Angeles
Featured Publications:
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer
See Other Senior R&D Staff Profiles
Calvin Jan, Ph.D.
Principal Investigator
David Kelley, Ph.D.
Principal Investigator
Magdalena Lopez, Ph.D.
Director, Cellular Models & Assay Technologies
Wen Lu, Ph.D.
Principal Investigator
PREVIOUS BIO    NEXT BIO
About Us
Research & Technology
Drug Development
Leadership
Partnering
Our Story
Life at Calico
Resources
Publications
Calico Stories
News & Media
Patients
Contact Us
Contact Us
Join Us
Follow Us
X
LinkedIn
Privacy Policy
Notice at Collection
Terms of Use
Code of Conduct
2026 Calico Life Sciences LLC. All rights reserved.
Close